7KPG
Blocking Fab 25 anti-SIRP-alpha antibody in complex with SIRP-alpha Variant 1
7KPG の概要
エントリーDOI | 10.2210/pdb7kpg/pdb |
分子名称 | Heavy chain of Fab 25 anti-SIRP-alpha antibody, Light chain of Fab 25 anti-SIRP-alpha antibody, Tyrosine-protein phosphatase non-receptor type substrate 1, ... (5 entities in total) |
機能のキーワード | sirpa antibody complex, signal regulatory protein alpha variant 1, signaling protein |
由来する生物種 | Homo sapiens (Human) 詳細 |
タンパク質・核酸の鎖数 | 3 |
化学式量合計 | 58197.51 |
構造登録者 | |
主引用文献 | Kuo, T.C.,Chen, A.,Harrabi, O.,Sockolosky, J.T.,Zhang, A.,Sangalang, E.,Doyle, L.V.,Kauder, S.E.,Fontaine, D.,Bollini, S.,Han, B.,Fu, Y.X.,Sim, J.,Pons, J.,Wan, H.I. Targeting the myeloid checkpoint receptor SIRP alpha potentiates innate and adaptive immune responses to promote anti-tumor activity. J Hematol Oncol, 13:160-160, 2020 Cited by PubMed Abstract: Signal regulatory protein α (SIRPα) is a myeloid-lineage inhibitory receptor that restricts innate immunity through engagement of its cell surface ligand CD47. Blockade of the CD47-SIRPα interaction synergizes with tumor-specific antibodies and T-cell checkpoint inhibitors by promoting myeloid-mediated antitumor functions leading to the induction of adaptive immunity. Inhibition of the CD47-SIRPα interaction has focused predominantly on targeting CD47, which is expressed ubiquitously and contributes to the accelerated blood clearance of anti-CD47 therapeutics. Targeting SIRPα, which is myeloid-restricted, may provide a differential pharmacokinetic, safety, and efficacy profile; however, SIRPα polymorphisms and lack of pan-allelic and species cross-reactive agents have limited the clinical translation of antibodies against SIRPα. Here, we report the development of humanized AB21 (hAB21), a pan-allelic anti-SIRPα antibody that binds human, cynomolgus monkey, and mouse SIRPα alleles with high affinity and blocks the interaction with CD47. PubMed: 33256806DOI: 10.1186/s13045-020-00989-w 主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.27 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード